Janney Montgomery Scott
VTGN icon

Janney Montgomery Scott’s VistaGen Therapeutics VTGN Stock Holding History

Janney Montgomery Scott’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$51K – 2840
2023
Q4 		$51K Buy
+10,000
New +$37.8K ﹤0.01% 2583

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janney Montgomery Scott's VTGN Position: Q1 2024 in Review

Janney Montgomery Scott sold out of VistaGen Therapeutics (VTGN) in Q1 2024, closing a stake of 10,000 shares — an estimated $51K sold.

Janney Montgomery Scott first reported a position in VTGN in Q4 2023 and held it in 1 quarter. The position peaked at $51K in Q4 2023. 42 funds tracked by Wall St. Rank hold VTGN as of Q1 2024.

  • Janney Montgomery Scott reported no remaining VistaGen Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Janney Montgomery Scott sold 10,000 VistaGen Therapeutics shares in Q1 2024, an estimated $51K.
  • Janney Montgomery Scott first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 1 quarter.
  • Janney Montgomery Scott's VistaGen Therapeutics position peaked at $51K in Q4 2023.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2024.

Based on Janney Montgomery Scott's 13F filing for Q1 2024, filed 1 May 2024.